Identification of a small molecule beta-secretase inhibitor that binds without catalytic aspartate engagement.

A small molecule inhibitor of beta-secretase with a unique binding mode has been developed. Crystallographic determination of the enzyme-inhibitor complex shows the catalytic aspartate residues in the active site are not engaged in inhibitor binding. This unprecedented binding mode in the field of aspartyl protease inhibition is described.

[1]  P. Saftig,et al.  Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.

[2]  Paul Zuck,et al.  Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. , 2008, Journal of medicinal chemistry.

[3]  M Katharine Holloway,et al.  Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. , 2004, Journal of medicinal chemistry.

[4]  Lin Hong,et al.  Crystal Structure of Memapsin 2 (β-Secretase) in Complex with an Inhibitor OM00-3† , 2002 .

[5]  D. Timm,et al.  P3 cap modified Phe*-Ala series BACE inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[6]  Rajiv Chopra,et al.  Acylguanidines as Small-Molecule β-Secretase Inhibitors , 2006 .

[7]  Arun K. Ghosh,et al.  Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 (β-Secretase) , 2001 .

[8]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[9]  Dongwoo Shin,et al.  Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase). , 2000, Journal of the American Chemical Society.

[10]  S. L. Winslow,et al.  Transport characteristics of peptides and peptidomimetics: II. Hydroxyethylamine bioisostere-containing peptidomimetics as substrates for the oligopeptide transporter and P-glycoprotein in the intestinal mucosa. , 2001, The journal of peptide research : official journal of the American Peptide Society.

[11]  A. Berger,et al.  On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. , 1968, Biochemical and biophysical research communications.

[12]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[13]  Manuel Buttini,et al.  Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice* , 2007, Journal of Biological Chemistry.

[14]  Joseph B. Moon,et al.  Design and Synthesis of Hydroxyethylene-Based Peptidomimetic Inhibitors of Human β-Secretase , 2004 .

[15]  Rudi D'Hooge,et al.  Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.

[16]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[17]  Eugene D. Thorsett,et al.  Design of Substrate-Based Inhibitors of Human β-Secretase , 2002 .

[18]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[19]  Martin Stahl,et al.  Tyramine fragment binding to BACE-1. , 2008, Bioorganic & medicinal chemistry letters.